Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 1,615 | 827 | 863 | 895 | 986 | 1,108 | 1,409 | 1,226 |
| Operating profit | €m | 68 | 120 | ||||||
| Net profit | €m | 74.3 | -40.9 | 4.3 | -38.5 | 10.1 | 46.2 | 71.7 | 85.1 |
| EPS reported | € | 0.22 | 0.33 | ||||||
| Operating cashflow per share | € | 0.79 | 1.51 | ||||||
| Capex per share | € | 0.16 | 0.14 | ||||||
| FCF per share | € | 0.63 | 1.51 | ||||||
| Free cash flow | €m | 134 | 329 | ||||||
| Net debt | €m | -38.2 | -30.8 | ||||||
| Book value equity | €m | 1,487 | 1,530 | ||||||
| Book value per share | € | 6.92 | 7.03 | ||||||
| Number of shares | m | 214.78 | 217.74 | ||||||
| DPS (TTM paid) | € | 0.18 | 0.18 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 58.36 | 30.43 | ||||||
| P/B LTM | x | 1.85 | 1.43 | ||||||
| P/S LTM | x | 2.49 | 1.56 | ||||||
| P/FCF LTM | x | 20.54 | 6.68 | ||||||
| EV/EBITDA LTM | x | 12.62 | 4.49 | ||||||
| EV/Sales LTM | x | 2.49 | 1.54 | ||||||
| Earnings Yield LTM | % | 1.71% | 3.29% | ||||||
| FCF Yield | % | 4.87% | 14.97% | ||||||
| Quality | |||||||||
| ROE | % | 3.11% | 4.78% | ||||||
| ROIC | % | 2.09% | 3.71% | ||||||
| Operating margin | % | 6.11% | 8.50% | ||||||
| Gross margin | % | 41.21% | 74.04% | ||||||
| FCF/Sales | % | 12.12% | 23.32% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +358.33% | +250.69% | ||||||
| Sales Growth YoY | % | +12.41% | +34.34% | ||||||
| Net Income Growth YoY | % | +355.31% | +236.25% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +87.65% | +540.27% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.95% | 1.83% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 55.44% | 5.33% | ||||||
| FCF/Debt | x | 0.39 | 0.90 | ||||||
| Net Debt/EBITDA | x | 0.02 | 0.02 | ||||||
| EBIT/Net interest | x | 3.79 | 5.22 | ||||||
| Net debt/market cap | % | -1.39% | -1.40% | ||||||
| Net debt/Equity | x | -0.03 | -0.02 | ||||||
| Gross debt/equity | x | 0.23 | 0.24 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its product line targets various dermatological ailments such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, alongside rare skin conditions. Beyond its core dermatology focus, the company also offers solutions for cardiovascular, musculoskeletal, respiratory, and nervous system disorders, as well as products for digestive health, anti-infectives for systemic use, genitourinary conditions and sex hormones, immunostimulants, and systemic hormonal preparations. Its extensive portfolio includes a range of well-known medications, such as Ilumetri, Solaraze, Skilarence, and Klisyri, among others. Almirall fosters strategic partnerships with numerous entities to advance its pipeline, including research institutions like the University of Dundee and commercial partners such as Eli Lilly and Company. Founded in Barcelona, Spain, in 1943, the company adopted its current name, Almirall, S.A., in May 2009, having previously been known as Laboratorios Almirall, S.A.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its product line targets various dermatological ailments such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, alongside rare skin conditions. Beyond its core dermatology focus, the company also offers solutions for cardiovascular, musculoskeletal, respiratory, and nervous system disorders, as well as products for digestive health, anti-infectives for systemic use, genitourinary conditions and sex hormones, immunostimulants, and systemic hormonal preparations. Its extensive portfolio includes a range of well-known medications, such as Ilumetri, Solaraze, Skilarence, and Klisyri, among others. Almirall fosters strategic partnerships with numerous entities to advance its pipeline, including research institutions like the University of Dundee and commercial partners such as Eli Lilly and Company. Founded in Barcelona, Spain, in 1943, the company adopted its current name, Almirall, S.A., in May 2009, having previously been known as Laboratorios Almirall, S.A.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free